Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.05. | Results of Aelis Farma Combined General Meeting of May 27, 2025 | 231 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
06.05. | Aelis Farma: Combined General Meeting of May 27, 2025: Availability of Preparatory Documents and Participation and Voting Procedures | 246 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
29.04. | Aelis Farma: Availability of the 2024 Universal Registration Document | 190 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
01.04. | Aelis Farma Reports Its 2024 Annual Financial Results and Confirms Its 2025 Outlook | 308 | Business Wire | 2024 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates:
AEF0117: announcement of the results of the Phase 2b clinical... ► Artikel lesen | |
AELIS FARMA Aktie jetzt für 0€ handeln | |||||
26.03. | Aelis Farma Announces the Final Analysis of the Landmark Phase 2B Clinical Trial in Cannabis Use Disorder (CUD) with the CB1-SSi AEF0117 | 326 | Business Wire | The purpose of this pioneering Phase 2B trial was to show that AEF0117 reduces cannabis use and to determine the endpoints and optimal dosage to be used in future studies. AEF0117 is the first... ► Artikel lesen | |
17.02. | Aelis Farma Announces Its 2025 Financial Calendar | 259 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
18.11.24 | Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults With Down Syndrome | 339 | Business Wire | The CB1-SSi AEF0217 successfully met the safety (primary), pharmacokinetic (secondary) and efficacy (secondary and exploratory) objectives of this phase 1/2 performed in young adults with Down... ► Artikel lesen | |
26.09.24 | Aelis Farma: Availability of the 2024 Half-year Financial Report | 282 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces that its half-year... ► Artikel lesen | |
25.09.24 | Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update | 371 | Business Wire | A solid cash position of €12.6 million at June 30, 2024, not including the gross amount of €4.5 million share offering which occurred at the end of July and other non-dilutive financing currently... ► Artikel lesen | |
04.09.24 | Indivior PLC: Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder | 451 | PR Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN... ► Artikel lesen | |
04.09.24 | Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD) | 414 | Business Wire | The main objective of this phase 2B study was to demonstrate that AEF0117 reduces cannabis use and to determine the endpoints as well as the optimal dosage of AEF0117 for use in future studies.... ► Artikel lesen | |
31.07.24 | Aelis Farma Announces the Successful Completion of Its Reserved Offering for a Total Gross Amount of €4.5 Million | 478 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS the "Company"), a... ► Artikel lesen | |
30.07.24 | Aelis Farma: Launch of a Reserved Offering of Approximately €5 Million | 545 | Business Wire | NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN Launch of a Reserved Offering of new shares for c. €5 million aimed at categories... ► Artikel lesen | |
24.06.24 | Aelis Farma: Availability of the Description of the Share Buyback Program | 303 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,105 | -0,43 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
BIONTECH | 96,60 | +0,36 % | Allianz gegen Krebs: BioNTech sichert sich Milliarden-Deal mit Bristol Myers: Aktie explodiert! | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech erhält 1,5 Milliarden US-Dollar Vorschuss von Bristol Myers - für die gemeinsame Entwicklung eines vielversprechenden Krebswirkstoffs.... ► Artikel lesen | |
MODERNA | 23,450 | -0,42 % | Allianz, Amazon, Deutsche Konsum, Gerresheimer, Hensoldt, Moderna - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,785 | -0,01 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
EVOTEC | 7,006 | +0,17 % | DAX nach Feiertag wieder bei 24.000 - Douglas, Evotec, Fresenius, Merck, Renk und SAP im Check | An Christi Himmelfahrt hat es am deutschen Aktienmarkt bei dünnen Umsätzen etwas an Boden verloren. Die Verluste macht der DAX aber am letzten Handelstag im Mai schon wieder gut, wobei die Zollpolitik... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,550 | +4,21 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,995 | +9,18 % | Recursion Pharmaceuticals: MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy | ||
VERA THERAPEUTICS | 20,950 | -31,47 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
HEIDELBERG PHARMA | 4,760 | +5,78 % | Vorstands-Interview Exklusiv: Heidelberg Pharma - "Unsere innovative Krebstherapie ist angetreten, um Resistenzen zu überwinden" | Heidelberg Pharma hat sich mit einer klaren Mission dem Kampf gegen Krebs verschrieben: Therapien zu entwickeln, die wirksam, verträglich und vor allem eins können - Resistenzen überwinden. Mit einem... ► Artikel lesen | |
CUREVAC | 3,868 | -0,92 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
BEAM THERAPEUTICS | 18,110 | +6,53 % | Beam Therapeutics Announces Orphan Drug Designation For BEAM-101 | WASHINGTON (dpa-AFX) - Beam Therapeutics (BEAM) announced that the FDA has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 48,290 | -1,19 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
BB BIOTECH | 32,800 | 0,00 % | BB Biotech - Optimistic about biotech's long-term prospects | During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 11,280 | 0,00 % | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 | Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 434,80 | +2,96 % | Nasdaq 100 verliert 1,01 Prozent - Regeneron Pharmaceuticals mit größtem Kursverlust (21.148 Pkt.) | Für den Nasdaq 100-Index brachte der bisherige Aktienhandel heute leichte Verluste. Derzeit liegt das Kursbarometer mit 1,01 Prozent im Minus. Die Bären haben sich aktuell im Wertpapierhandel knapp... ► Artikel lesen |